Application of fecal ceramide marker in early warning of retained fetal membranes of dairy cow
By screening and combining fecal ceramide biomarkers, the problem of early warning of retained placenta in dairy cows has been solved, achieving highly accurate diagnosis, avoiding invasive testing, and improving the reliability of prediction.
Patent Information
- Application Number
- CN202511390955.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-26
- Publication Date
- 2025-12-02
AI Technical Summary
Existing technologies are insufficient for early warning of retained placenta in dairy cows. Traditional diagnostic methods rely on postpartum clinical symptoms and are highly invasive. Blood indicators have limited specificity and practicality, resulting in low predictive accuracy.
Fecal ceramide biomarkers, particularly combinations of Cer d18:1/4:0, Cer d18:0/12:0, Cer d18:1/16:0, Cer d18:1/18:0, and Cer d18:1/24:0, were screened and used in combination using lipidomics technology to prepare a kit for detection.
It enables early warning of retained placenta in dairy cows, improves the accuracy and reliability of diagnosis, has good stability of fecal samples, and provides reliable test results, avoiding the disadvantages of invasive testing.
Smart Images

Figure CN121049422A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of early diagnosis and metabolomics analysis technology in veterinary clinical diseases, specifically to the application of fecal ceramide biomarkers in early warning of retained placenta in dairy cows. Background Technology
[0002] Retained placenta (RP) is a common reproductive disorder during the peripartum period in dairy cows. Clinically, it is generally defined as the failure of the placenta to be expelled within a certain period after calving: some literature considers failure to expel the placenta for more than 8-12 hours as abnormal; in actual production, 24 hours is generally used as the threshold, meaning that if the placenta is not expelled within 24 hours after calving, it is considered retained placenta. This disease has a high incidence in dairy cows, averaging about 5% to 15% of calving cows; some studies have shown that the incidence of RP can reach 10% to 30%, and even as high as 50% in hot summer months. Retained placenta is caused by a variety of factors, including nutritional and metabolic disorders, abnormal hormone levels, decreased peripartum immune function, and the mode of delivery (such as dystocia, twins, etc.). Retained placenta not only occurs frequently but also poses serious risks to the postpartum health and reproductive performance of dairy cows. Affected cows are prone to secondary infections such as endometritis, mastitis, and uterine bacteremia, leading to decreased milk production, shortened lactation period, and reduced fertility (e.g., prolonged intervals between first estrus and mating, and increased days of non-pregnancy). Cows with retained placenta often require more mating attempts to conceive, and the intervals between subsequent pregnancies are prolonged, ultimately resulting in significant economic losses. Therefore, reducing the incidence of retained placenta in dairy herds is of great importance to dairy cow health and dairy production.
[0003] Currently, the diagnosis of retained placenta in dairy cows mainly relies on observation of postpartum clinical symptoms and manual examination, specifically whether the placenta was expelled on time after calving. However, by the time a clinical diagnosis is made, the disease has often already occurred, missing the optimal window for prevention. Among the indicators used to monitor the health status of dairy cows during the peripartum period, blood biochemical and hormonal indicators can, to some extent, suggest the risk of retained placenta. For example, studies have found elevated levels of non-esterified fatty acids (NEFA) and β-hydroxybutyrate (BHBA) in the blood of cows with retained placenta during the peripartum period, which are correlated with the occurrence of RP. Some serum acute-phase proteins and cytokines (such as IL-6 and TNF-α) show abnormalities several weeks before the onset of the disease. However, the detection of these blood indicators is invasive, and their specificity and practicality are limited, thus a reliable prepartum early warning method has not yet been established. In addition, traditionally, risk factors such as calving difficulty, parity, and nutritional status have been used to predict which cows may develop RP, but the accuracy of the prediction is limited. Summary of the Invention
[0004] The purpose of this invention is to provide the application of fecal ceramide biomarkers in the early warning of retained placenta in dairy cows.
[0005] The present invention adopts the following technical solution: The application of a fecal ceramide biomarker detection reagent in the preparation of a product for early warning of retained placenta in dairy cows, wherein the fecal ceramide biomarker is selected from one or any combination of Cer d18:1 / 4:0, Cer d18:0 / 12:0, Cer d18:1 / 16:0, Cer d18:1 / 18:0 and Cer d18:1 / 24:0.
[0006] This invention, based on lipidomics technology, screened five lipid compounds whose levels differed significantly between healthy and retained placenta cows' feces. Each of these five lipid compounds exhibited excellent diagnostic performance for retained placenta and can serve as effective biomarkers for its diagnosis. More importantly, the combined use of these five lipid compounds significantly improved diagnostic efficacy, enabling more precise identification of this pathological condition.
[0007] Furthermore, the product is a reagent kit.
[0008] Furthermore, the kit includes a lipid extraction reagent, which is a mixture of methanol and methyl tert-butyl ether in a volume ratio of 0.2~0.4:0.5~1.5.
[0009] Furthermore, the kit includes a liquid phase separation reagent.
[0010] Furthermore, the liquid phase separation reagent includes mobile phase A and mobile phase B. Mobile phase A is a mixture of acetonitrile and water in a volume ratio of 5~7:3~5, and mobile phase B is a mixture of isopropanol and acetonitrile in a volume ratio of 8~10:0.5~1.5. Both mobile phase A and mobile phase B contain 9~11 mmol / L of ammonium formate and 0.05~0.15% formic acid by volume.
[0011] Furthermore, the kit is used in conjunction with a detection device to detect the fecal ceramide markers.
[0012] Furthermore, the detection device includes a liquid chromatography-tandem mass spectrometer, and the detection reagent is used to detect the content of the fecal ceramide marker by liquid chromatography-tandem mass spectrometry.
[0013] Furthermore, the samples tested were peripartum dairy cow feces.
[0014] Furthermore, the feces are those from 2 to 8 days before the cows give birth.
[0015] Compared with the prior art, the beneficial effects of the present invention are as follows: This invention characterizes fecal ceramide biomarkers of retained placenta in dairy cows using liposome profiling and screens out fecal ceramide biomarkers for early warning of retained placenta in dairy cows. The obtained lipid biomarkers have high value for early prediction and identification of retained placenta in dairy cows.
[0016] The lipid biomarkers screened by this invention have good biological stability and representativeness, and their biological activity can be maintained even after long-term storage of fecal samples, thus ensuring the reliability of the detection results. Attached Figure Description
[0017] Figure 1 Differences in ceramide levels between retained placenta (RP) and control (CON) dairy cows were screened for fecal non-targeted lipidomics analysis. Figure A shows a volcano plot illustrating the difference in fecal lipid levels between the RP and CON groups 7 days before calving, and Figure B shows a volcano plot illustrating the difference in fecal lipid levels between the RP and CON groups 3 days before calving. The horizontal axis represents the logarithmic transformation value (Log2FC) of the difference, and the vertical axis represents the negative logarithmic transformation value (-Log10 P value) of the significance test. Red dots (up) indicate significantly upregulated differentially regulated metabolites, green dots (down) indicate significantly downregulated differentially regulated metabolites, and blue dots (nosig) indicate metabolites with no significant difference. The size of the dots represents the VIP (Variable Importance in Projection) value. Detailed Implementation
[0018] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments, but this should not be construed as limiting the invention. Unless otherwise specified, the technical means used in the following embodiments are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following embodiments are commercially available unless otherwise specified.
[0019] Implementation 1: Screening for fecal ceramide biomarkers.
[0020] I. Materials and Methods.
[0021] 1. Animal grouping The study was conducted at the Beijing Shou Nong Livestock Jin Yin Dao Ranch, which maintains a stable population of over 2,000 lactating dairy cows year-round. The ranch employs standardized feeding and management practices and has a comprehensive system for recording calving and monitoring diseases in dairy cows. The study subjects were healthy, multiparous dairy cows awaiting calving, with parities of 2-4 and a Body Condition Score (BCS) between 2.75 and 3.5. The calving and placental expulsion of the cows were continuously monitored throughout the peripartum period. Fifty cows meeting the experimental criteria were selected and grouped according to whether the placenta was expelled on time after calving.
[0022] Retained placenta group (RP group): Cows that have not expelled the placenta naturally within 24 hours after calving are defined as having "retained placenta", totaling 25 cows.
[0023] Normal delivery control group (CON group): Dairy cows whose placenta was completely and naturally expelled within 8 hours after calving, and who had no record of dystocia or assisted delivery, served as the healthy control group, consisting of 25 cows.
[0024] There were no significant differences between the two groups of dairy cows in terms of parity, sex of calving, difficulty of calving, and body condition score, which can ensure the reliability of subsequent metabolomics analysis.
[0025] 2. Sample collection Fresh fecal samples were collected from all calving cows via rectal sampling 7 days and 3 days before their expected calving date, with approximately 30g collected from each cow. The samples were placed in sterile centrifuge tubes, immediately pre-cooled in liquid nitrogen, and then stored in an ultra-low temperature freezer at -80°C until analysis.
[0026] Blood samples were collected from dairy cows on days 7 and 3 prior to their expected calving date. Blood was collected via tail vein coccygeal venipuncture and immediately placed in vacuum blood collection tubes containing a coagulant (Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and rapidly stored on ice. Serum was separated by centrifugation at 2000g for 20 minutes within one hour of collection. Non-esterified fatty acids (NEFA) were measured using an enzymatic colorimetric method (kit number: A042-2-1, Nanjing Jiancheng Bioengineering Institute, Nanjing), following the kit instructions. β-hydroxybutyrate (BHBA) was measured using an enzymatic colorimetric method (kit number: E030-1-1, Nanjing Jiancheng Bioengineering Institute, Nanjing), following the manufacturer's instructions. All absorbance values were measured using a microplate reader (Multiskan FC, Thermo Fisher Scientific, USA). The coefficients of variation within and between groups were both less than 10%.
[0027] 3. Fecal non-targeted lipidomics analysis Remove fecal samples from the -80°C freezer and thaw slowly on ice. Take approximately 100 mg (±5 mg) of each sample and place it into a pre-chilled 2 mL EP tube. Add one grinding bead to the EP tube, freeze thoroughly in liquid nitrogen, and then mechanically grind the fecal sample using a tissue homogenizer (Wonbio-96c; Shanghai Wanbai Biotechnology Co., Ltd.) (frequency 50 Hz, time 60 s) to thoroughly pulverize the fecal sample.
[0028] Add 300 μL of methanol and 1 mL of methyl tert-butyl ether (MTBE) sequentially to the sample, and vortex for 1 minute. Place the sample in an ice-water bath and sonicate for 20 minutes to fully release lipids (SBL-10DT ultrasonic cleaner 300W-10L, Ningbo Xinzhi Biotechnology Co., Ltd.). Add 250 μL of LC-MS grade ultrapure water to separate the phases. Vortex again for 1 minute and let stand for 10 minutes. Centrifuge at 12000g, 4℃ for 15 minutes (Centrifuge 5430R, Eppendorf GmbH, Germany), and collect the upper organic phase (containing lipids). Transfer the upper organic phase to a new glass inner tube and dry the sample at room temperature using a nitrogen blower (JXDC-20; Shanghai Jingxin Industrial Development Co., Ltd.). After drying, the lipids were resuspended in 200 μL of isopropanol / acetonitrile (1:1, v / v), vortexed, filtered through a 0.22 μm filter membrane, and transferred to an autosampler vial for LC-MS analysis.
[0029] The samples were analyzed by LC-MS / MS using a Thermo Fisher Scientific UHPLC-Q Exactive HF-X system.
[0030] Chromatographic conditions: Column: ACQUITY UPLC BEH C18 (2.1 × 100 mm, 1.7 μm). Mobile phase A: Composed of 60% acetonitrile + 40% water, with the addition of 10 mmol / L ammonium formate and 0.1% formic acid. Mobile phase B: Composed of 90% isopropanol + 10% acetonitrile, with the addition of 10 mmol / L ammonium formate and 0.1% formic acid. Flow rate: 0.3 mL / min; Column temperature: 45℃; Injection volume: 5 μL. Mixed quality control (QC) samples were set up, with one sample inserted every 6 pins, to check the stability of the total ion current (TIC) chromatogram of the QC samples.
[0031] Elution gradients are shown in Table 1: Table 1: Elution gradient Mass spectrometry conditions: Ion source mode: ESI dual-mode acquisition of positive and negative ions; Scanning method: Information-dependent acquisition (IDA); Mass range: m / z 100–1500; Curtain gas pressure: 35psi; Electrospray voltage: positive ion mode +5500V, negative ion mode -4500V; Ion source temperature: 550℃; Declustering voltage: 100V; Collision energy: 35±15eV.
[0032] Data Analysis: Progenesis QI was used to perform peak identification, peak extraction, retention time alignment, and normalization on the raw mass spectrometry data; lipid metabolite annotation was performed using the LIPID MAPS database. Peaks with an RSD (relative standard deviation) >30% were removed to ensure data quality. Principal component analysis (PCA) was used to assess intragroup consistency and intergroup discrimination; partial least squares discriminant analysis (PLS-DA) was used to construct a region classification model; and differential markers were screened using the model's VIP (projected importance value) and one-way t-test: VIP > 1 and P < 0.05 were considered statistically significant.
[0033] II. Results Analysis.
[0034] 1. Serum NAFE and BHBA As shown in Table 2, the serum non-esterified fatty acid (NEFA) and β-hydroxybutyrate (BHBA) concentrations in dairy cows in the retained placenta group (RP group) were significantly higher than those in the normal group (CON group) at 7 days and 3 days before calving. Specifically: at 7 days before calving, the NEFA concentration in the RP group was 0.540 mmol / L, significantly higher than the 0.266 mmol / L in the CON group (P=0.032); at 3 days before calving, the NEFA concentration in the RP group was 0.792 mmol / L, significantly higher than the 0.381 mmol / L in the CON group (P=0.010). At 7 days before calving, the BHBA concentration in the RP group was 0.488 mmol / L, higher than the 0.290 mmol / L in the CON group (P=0.036); at 3 days before calving, the BHBA concentration in the RP group was 0.616 mmol / L, higher than the 0.394 mmol / L in the CON group (P=0.030).
[0035] Table 2: Serum NEFA and BHBA concentrations in dairy cows before calving in the normal group and the retained placenta group NEFA: Non-esterified fatty acids; BHBA: β-hydroxybutyric acid 2. Fecal non-targeted lipids Based on non-targeted lipidomics analysis using UHPLC-MS / MS, the differences in fecal lipid profiles between dairy cows in the retained placenta (RP) group and the normal control (CON) group were compared 7 days (7d) and 3 days (3d) before calving. Figure 1The results showed that 7 days before delivery, 17 lipids were significantly upregulated and 16 were significantly downregulated in the RP group, while the remaining 621 showed no significant difference. 3 days before delivery, 25 lipids were significantly upregulated and 10 were significantly downregulated in the RP group, while the remaining 630 showed no significant difference. Among the significantly upregulated lipids, five ceramide compounds that were upregulated at both time points, had high VIP values (>1), and passed the univariate significance test (P<0.05) were identified: Cer(d18:1 / 4:0), Cer(d18:0 / 12:0), Cer(d18:1 / 16:0), Cer(d18:1 / 18:0), and Cer(d18:1 / 24:0). The relative abundance of these five ceramides in the RP group was significantly higher than that in the CON group, suggesting that these ceramides may gradually accumulate before delivery and are associated with the risk of retained placenta.
[0036] As shown in Table 3, the area under the curve (AUC) values of the five differentially expressed ceramides were all above 0.852 at 7 days and 3 days before delivery, significantly higher than NEFA (0.778–0.801) and BHBA (0.762–0.790), suggesting higher predictive accuracy before delivery. Among them, Cer(d18:1 / 24:0) had the highest AUC value at 0.932 at 3 days before delivery.
[0037] To further evaluate the diagnostic performance of fecal differential ceramides in predicting retained placenta, a combined ROC curve analysis was performed on five ceramides (Cer(d18:1 / 4:0), Cer(d18:0 / 12:0), Cer(d18:1 / 16:0), Cer(d18:1 / 18:0), and Cer(d18:1 / 24:0)), and the AUC value was compared with that of the combined NEFA+BHBA. The results showed that the AUC of the combined five ceramides was 0.940 at 7 days preterm and 0.960 at 3 days preterm; while the AUC of the combined NEFA+BHBA was 0.823 at 7 days preterm and 0.846 at 3 days preterm. Regardless of whether it was 7 days or 3 days preterm, the AUC value of the combined five ceramides was significantly higher than that of the combined NEFA+BHBA, and the diagnostic performance was further improved at 3 days preterm. The results suggest that the combined detection of five differentially expressed ceramides in feces has higher predictive accuracy and clinical application potential for retained placenta, and can serve as a combination of non-invasive biomarkers superior to traditional energy metabolism indicators.
[0038] Table 3: ROC curve analysis results (AUC values) of ceramide, NEFA, and BHBA at 7 days and 3 days before delivery. Validation Example 1: Validation of fecal targeting of ceramides in an independent cohort in a pasture.
[0039] I. Materials and Methods.
[0040] Five differentially expressed ceramides selected in Experiment 1 were targeted and quantitatively validated in independent samples to assess their early warning value for retained placenta (RP) and compared with the diagnostic performance of serum NEFA and BHBA.
[0041] 1. Animals and Grouping New cases were continuously tracked in another batch of peripartum dairy cows at the same large-scale dairy farm in Beijing. Thirty multiparous cows were included and grouped according to the expulsion of the placenta after calving: RP group (n=15): The placenta was not expelled naturally within 24 hours postpartum; CON group (n=15): The placenta was expelled naturally within 8 hours postpartum and there was no record of dystocia / assisted delivery.
[0042] There were no significant differences between the two groups in parity (2-4 pregnancies) and body condition score (2.75-3.5).
[0043] 2. Sampling time and sample preservation Fresh feces (approximately 30g per animal at each time point) were collected rectally at two time points: 7 days before delivery (7d) and 3 days before delivery (3d). The feces were then numbered, flash-frozen in liquid nitrogen, and stored at −80℃ for later analysis. Serum NEFA and BHBA levels were collected and measured concurrently according to Experiment 1 procedure for comparison.
[0044] 3. Targeted ceramide LC-MS / MS quantification Five Cer standards were purchased, with target compounds: Cer(d18:1 / 4:0), Cer(d18:0 / 12:0), Cer(d18:1 / 16:0), Cer(d18:1 / 18:0), and Cer(d18:1 / 24:0), all purchased from AvantiPolarLipids (USA) (Table 4).
[0045] Table 4: CAS Numbers and Supplier Information for 5 Types of Cer Extraction: Take 100 mg (wet weight) of each sample, add 300 μL methanol + 1 mL MTBE, and sonicate on ice for 20 min; add 250 μL water to promote phase separation, centrifuge at 12000 g, 4 °C for 15 min, and dry the supernatant with nitrogen; resuspend in 200 μL isopropanol / acetonitrile (v:v=1:1), filter through a 0.22 μm filter membrane, and analyze. Results are expressed as ng / g feces (wet weight).
[0046] Instrument: UHPLC-Triple Quadrupole MS (Thermo TSQ / AB 6500+). Column: BEH C18, 2.1×100mm, 1.7μm; flow rate: 0.30mL / min; column temperature: 45℃; injection volume: 5μL. Mobile phase: A: 60% acetonitrile + 40% water, containing 10mmol / L ammonium formate and 0.1% formic acid; B: 90% isopropanol + 10% acetonitrile, containing 10mmol / L ammonium formate and 0.1% formic acid. Gradient: Same as in Example 1. Ion source: ESI positive ion mode; curtain gas 35psi; spray voltage +5500V; source temperature 550℃; declustering voltage 100V. Acquisition method: MRM multiple reaction monitoring.
[0047] Standard solutions of different concentrations (0.01 ng / mL, 0.02 ng / mL, 0.05 ng / mL, 0.1 ng / mL, 0.2 ng / mL, 0.5 ng / mL, 1 ng / mL, 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 50 ng / mL, 100 ng / mL, 200 ng / mL, 500 ng / mL, 1000 ng / mL, 2000 ng / mL, and 5000 ng / mL) were prepared, and standard curves for different substances were plotted, as shown in Table 5.
[0048] Table 5: Standard Curves for 5 Types of Cer The ratio of the integrated peak area (x) of all detected samples is substituted into the linear equation of the standard curve to calculate the content (y) of the substance in the actual sample.
[0049] II. Results.
[0050] As shown in Table 6, compared with the normal group, the serum NEFA and BHBA concentrations in the retained placenta group were significantly higher at 7 days and 3 days before calving (P < 0.05). Specifically, the NEFA levels in the retained placenta group were 0.532 mmol / L and 0.776 mmol / L at 7 days and 3 days before calving, respectively, both significantly higher than those in the normal group (0.251 mmol / L and 0.372 mmol / L); the BHBA levels were 0.491 mmol / L and 0.667 mmol / L at 7 days and 3 days before calving, respectively, both significantly higher than those in the normal group (0.275 mmol / L and 0.380 mmol / L).
[0051] Table 6: Serum NEFA and BHBA concentrations before calving in normal and retained placenta groups of dairy cows In fecal targeted ceramide analysis, the results showed that the concentrations of Cer(d18:1 / 4:0), Cer(d18:0 / 12:0), Cer(d18:1 / 16:0), Cer(d18:1 / 18:0), and Cer(d18:1 / 24:0) in the retained placenta group (RP) were significantly higher than those in the normal group (CON) at 7 days and 3 days before calving (P<0.05). Among them, the difference in Cer(d18:1 / 24:0) was the most significant at both time points (P<0.001). The overall results indicate that these five fecal ceramides show a continuous upward trend before calving, and the differences are more pronounced as calving approaches, suggesting that they can serve as potential biomarkers for early warning of retained placenta.
[0052] Table 7: Targeted analysis of Cere concentration in prepartum feces of dairy cows in the normal group and the retained placenta group The AUC values of the five fecal ceramides were significantly higher than those of NEFA and BHBA at both 7 and 3 days before delivery. Cer(d18:1 / 24:0) showed the highest AUC values at both time points (0.903 and 0.934, respectively), demonstrating strong ability to detect retained placenta. In contrast, the AUC values of NEFA and BHBA were both below 0.78, suggesting that the predictive performance of traditional energy metabolism indicators is inferior to that of fecal ceramides.
[0053] Table 8: ROC curve analysis results (AUC values) of ceramide, NEFA and BHBA at 7 days and 3 days before delivery. This study systematically evaluated the application potential of fecal ceramides (Cer) in early warning of retained placenta (RP) in peripartum dairy cows through non-targeted and targeted lipidomics analysis. Non-targeted lipidomics screening revealed that Cer(d18:1 / 4:0), Cer(d18:0 / 12:0), Cer(d18:1 / 16:0), Cer(d18:1 / 18:0), and Cer(d18:1 / 24:0) were significantly elevated 7 days and 3 days before calving in RP cows, and their predictive efficacy (AUC) was significantly better than serum NEFA and BHBA. Independent cohort targeted validation further confirmed that the concentration trends of these five Cer types at different time points were consistent with the discovery phase, with Cer(d18:1 / 24:0) exhibiting the highest predictive ability. The results showed that fecal ceramides can serve as a stable, non-invasive, and highly specific biomarker for identifying high-risk RP (retained placenta) dairy cows before calving, providing a scientific basis for early intervention in dairy farms and potentially improving the efficiency of prevention and control of retained placenta and the reproductive health of dairy cows.
[0054] Although preferred embodiments of the invention have been described, those skilled in the art, upon learning the basic inventive concept, can make other changes and modifications to these embodiments. Therefore, the appended claims are intended to be interpreted as including both the preferred embodiments and all changes and modifications falling within the scope of the invention.
[0055] Obviously, those skilled in the art can make various modifications and variations to this invention without departing from its spirit and scope. Therefore, if these modifications and variations fall within the scope of the claims of this invention and their equivalents, this invention also intends to include these modifications and variations.
Claims
1. The application of a fecal ceramide marker detection reagent in the preparation of a product for early warning of retained placenta in dairy cows, characterized in that, The fecal ceramide markers are selected from one or any combination of Cer d18:1 / 4:0, Cer d18:0 / 12:0, Cer d18:1 / 16:0, Cer d18:1 / 18:0 and Cer d18:1 / 24:
0.
2. The application according to claim 2, characterized in that, The product in question is a reagent kit.
3. The application according to claim 1, characterized in that, The kit includes a lipid extraction reagent, which is a mixture of methanol and methyl tert-butyl ether in a volume ratio of 0.2~0.4:0.5~1.
5.
4. The application according to claim 1, characterized in that, The kit includes liquid phase separation reagents.
5. The application according to claim 4, characterized in that, The liquid phase separation reagent includes mobile phase A and mobile phase B. Mobile phase A is a mixture of acetonitrile and water in a volume ratio of 5~7:3~5, and mobile phase B is a mixture of isopropanol and acetonitrile in a volume ratio of 8~10:0.5~1.
5. Both mobile phase A and mobile phase B contain 9~11 mmol / L of ammonium formate and 0.05~0.15% formic acid by volume.
6. The application according to claim 2, characterized in that, The kit is used in conjunction with the detection device to detect the fecal ceramide markers.
7. The application according to claim 6, characterized in that, The detection device includes a liquid chromatography-tandem mass spectrometer, and the content of the fecal ceramide marker is obtained by detecting the detection reagent using liquid chromatography-tandem mass spectrometry.
8. The application according to claim 7, characterized in that, The samples tested were peripartum dairy cow feces.
9. The application according to claim 8, characterized in that, The feces mentioned are those from dairy cows 2 to 8 days before calving.
